Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 213

1.

Vasoactive intestinal peptide increases VEGF expression to promote proliferation of brain vascular endothelial cells via the cAMP/PKA pathway after ischemic insult in vitro.

Yang J, Shi QD, Song TB, Feng GF, Zang WJ, Zong CH, Chang L.

Peptides. 2013 Apr;42:105-11. doi: 10.1016/j.peptides.2013.01.007. Epub 2013 Jan 20.

PMID:
23340020
2.

Vasoactive intestinal peptide in rats with focal cerebral ischemia enhances angiogenesis.

Yang J, Zong CH, Zhao ZH, Hu XD, Shi QD, Xiao XL, Liu Y.

Neuroscience. 2009 Jun 30;161(2):413-21. doi: 10.1016/j.neuroscience.2009.03.052. Epub 2009 Mar 28.

PMID:
19332106
3.

[Vasoactive intestinal peptide enhances angiogenesis after focal cerebral ischemia].

Yang J, Zong CH, Zhao CH, Qian YH, Hu XD, Liu Y.

Nan Fang Yi Ke Da Xue Xue Bao. 2009 Apr;29(4):619-22. Chinese.

4.

Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation.

St Hilaire RC, Murthy SN, Kadowitz PJ, Jeter JR Jr.

Peptides. 2010 Aug;31(8):1517-22. doi: 10.1016/j.peptides.2010.04.024. Epub 2010 May 7.

PMID:
20452385
5.
6.

Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells.

Valdehita A, Carmena MJ, Collado B, Prieto JC, Bajo AM.

Regul Pept. 2007 Dec 4;144(1-3):101-8. Epub 2007 Jun 28.

PMID:
17683807
7.

Effect of VIP on intracellular [Ca2+], extracellular regulated kinase 1/2, and secretion in cultured rat conjunctival goblet cells.

Li D, Jiao J, Shatos MA, Hodges RR, Dartt DA.

Invest Ophthalmol Vis Sci. 2013 Apr 23;54(4):2872-84. doi: 10.1167/iovs.12-11264.

8.

Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells.

Collado B, Gutiérrez-Cañas I, Rodríguez-Henche N, Prieto JC, Carmena MJ.

Regul Pept. 2004 Jun 15;119(1-2):69-75.

PMID:
15093699
9.

Vasoactive intestinal peptide (VIP) stimulates cortisol secretion from the H295 human adrenocortical tumour cell line via VPAC1 receptors.

Nicol MR, Cobb VJ, Williams BC, Morley SD, Walker SW, Mason JI.

J Mol Endocrinol. 2004 Jun;32(3):869-77.

PMID:
15171718
10.

VIP protects human retinal microvascular endothelial cells against high glucose-induced increases in TNF-α and enhances RvD1.

Shi H, Carion TW, Jiang Y, Steinle JJ, Berger EA.

Prostaglandins Other Lipid Mediat. 2016 Mar;123:28-32. doi: 10.1016/j.prostaglandins.2016.03.001. Epub 2016 Mar 26.

12.
13.

Coronary vascular effects of vasoactive intestinal peptide in the isolated perfused rat heart.

Sawmiller DR, Henning RJ, Cuevas J, Dehaven WI, Vesely DL.

Neuropeptides. 2004 Oct;38(5):289-97.

PMID:
15464194
14.
15.
16.

Phosphorylation of GRK2 by PKA augments GRK2-mediated phosphorylation, internalization, and desensitization of VPAC2 receptors in smooth muscle.

Murthy KS, Mahavadi S, Huang J, Zhou H, Sriwai W.

Am J Physiol Cell Physiol. 2008 Feb;294(2):C477-87. Epub 2007 Dec 12.

17.
18.

VIP induces NF-κB1-nuclear localisation through different signalling pathways in human tumour and non-tumour prostate cells.

Fernández-Martínez AB, Carmena MJ, Bajo AM, Vacas E, Sánchez-Chapado M, Prieto JC.

Cell Signal. 2015 Feb;27(2):236-44. doi: 10.1016/j.cellsig.2014.11.005. Epub 2014 Nov 15.

PMID:
25446255
19.

The cyclic AMP effects and neuroprotective activities of PACAP and VIP in cultured astrocytes and neurons exposed to oxygen-glucose deprivation.

Jóźwiak-Bębenista M, Kowalczyk E, Nowak JZ.

Pharmacol Rep. 2015 Apr;67(2):332-8. doi: 10.1016/j.pharep.2014.10.001. Epub 2014 Oct 16.

PMID:
25712659
20.

Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation.

Vacas E, Fernández-Martínez AB, Bajo AM, Sánchez-Chapado M, Schally AV, Prieto JC, Carmena MJ.

Biochim Biophys Acta. 2012 Oct;1823(10):1676-85. doi: 10.1016/j.bbamcr.2012.06.018. Epub 2012 Jun 21.

Supplemental Content

Support Center